Zollinger‑Ellison syndrome – peptic pain - Causes, Treatment & When to See a Doctor

What is Zollinger‑Ellison syndrome – peptic pain?

Zollinger‑Ellison syndrome (ZES) is a rare neuroendocrine tumor condition in which one or more gastrin‑producing cells (gastrinomas) develop in the pancreas or duodenum. The excess gastrin stimulates the stomach lining to secrete large amounts of gastric acid. This hyper‑acidity overwhelms the protective mechanisms of the upper gastrointestinal (GI) tract, leading to severe, recurrent peptic pain—often described as a burning or gnawing discomfort that may be felt in the upper abdomen, chest, or back.

While the classic triad of ZES consists of peptic ulcer disease, severe gastro‑esophageal reflux, and diarrhea, many patients first seek care because of relentless epigastric pain that does not respond to usual antacid therapy. Early recognition is essential because untreated ZES can cause multiple ulcers, bleeding, perforation, and, in rare cases, malignant transformation of the gastrinoma.

Sources: Mayo Clinic; CDC.

Common Causes

Peptic pain in ZES is driven by the underlying gastrinoma, but several related conditions can mimic or contribute to the symptom. Below are the most frequent causes of peptic‑type pain that clinicians consider when evaluating a patient:

• Gastrinoma (Zollinger‑Ellison syndrome) – the primary cause.
• Helicobacter pylori infection – a bacterial infection that weakens mucosal defenses.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs) – inhibit prostaglandin production, promoting ulceration.
• Benign peptic ulcer disease (PUD) – usually related to H. pylori or NSAIDs.
• Gastro‑esophageal reflux disease (GERD) – acidic reflux can mimic ulcer pain.
• Pancreatic neuroendocrine tumor (non‑gastrinoma) – may produce other hormones causing abdominal pain.
• Duodenal ulcer – often presents with pain that improves after meals.
• Hyperparathyroidism (part of MEN1) – associated with ZES in multiple endocrine neoplasia type 1.
• Chronic gastritis – inflammation of the stomach lining that can cause burning pain.
• Stress‑related ulceration (Curling’s ulcer, Cushing’s ulcer) – seen in severe burns or head injury.

Associated Symptoms

Because excess acid affects the entire upper GI tract, patients with ZES often develop a cluster of symptoms in addition to peptic pain:

• Recurrent or multiple ulcers – often in unusual locations (duodenum, jejunum).
• Heartburn and acid reflux – burning sensation behind the breastbone.
• Diarrhea or watery stools – acid inactivates pancreatic enzymes, leading to malabsorption.
• Weight loss – due to chronic diarrhea and reduced intake from pain.
• Vomiting of blood (hematemesis) or coffee‑ground material – sign of ulcer bleeding.
• Fatigue or anemia – from chronic blood loss.
• Abdominal fullness or bloating – secondary to gastric hyper‑secretion.
• Steatorrhea (fatty stools) – malabsorption from pancreatic enzyme inactivation.

When to See a Doctor

Peptic pain that is persistent, worsening, or accompanied by any of the following warrants prompt medical evaluation:

• Pain that does not improve with over‑the‑counter antacids or proton‑pump inhibitors (PPIs).
• Bleeding signs: vomiting blood, black/tarry stools, or unexplained bruising.
• Unexplained weight loss greater than 5 % of body weight in a month.
• Persistent diarrhea (more than three loose stools per day for >2 weeks).
• Severe, sudden onset of upper‑abdominal pain that radiates to the back.
• Repeated episodes of ulcer disease despite treatment.
• Family history of MEN1 (multiple endocrine neoplasia type 1) or known gastrin‑producing tumors.

Early evaluation can prevent complications such as ulcer perforation, severe bleeding, or malignant spread.

Diagnosis

Diagnosing ZES involves a stepwise approach that combines clinical suspicion with laboratory, imaging, and endoscopic studies.

1. Laboratory Tests

• Fasting serum gastrin level – markedly elevated (>1000 pg/mL) is strongly suggestive; values >10× upper limit are diagnostic in the appropriate clinical context.
• Secretin stimulation test – paradoxical rise in gastrin after IV secretin confirms gastrinoma.
• Gastric pH measurement – a pH <2 indicates active hyper‑acidity.
• Basic metabolic panel to assess electrolyte disturbances from diarrhea.

2. Imaging Studies

• Endoscopic ultrasound (EUS) – high‑resolution visualization of pancreatic and duodenal lesions.
• Multiphasic contrast‑enhanced CT or MRI – locates primary tumor and evaluates for metastasis.
• Somatostatin receptor scintigraphy (Octreoscan) or Ga‑68 DOTATATE PET/CT – detects gastrinomas that express somatostatin receptors.

3. Endoscopic Evaluation

• Upper endoscopy (EGD) – identifies ulcer number, size, and location; biopsies are taken to rule out malignancy.
• In selected cases, capsule endoscopy or double‑balloon enteroscopy may be used to inspect the jejunum.

4. Genetic Testing

If a patient has a family history suggestive of MEN1, genetic testing for the MEN1 gene mutation is recommended.

All diagnostic steps should be coordinated by a gastroenterologist and an endocrine surgeon experienced with neuroendocrine tumors. Sources: Cleveland Clinic; NIH Journal of Clinical Endocrinology.

Treatment Options

Treatment aims to control gastric acid hyper‑secretion, heal existing ulcers, and remove or control the gastrinoma.

Medical Management

• High‑dose Proton Pump Inhibitors (PPIs) – omeprazole, esomeprazole, or pantoprazole 40–80 mg daily (often divided doses). PPIs are the cornerstone, normalizing gastric pH and allowing ulcer healing.
• Histamine‑2 receptor antagonists (H2 blockers) – may be added for breakthrough symptoms, though less effective than PPIs.
• Antacids – provide symptomatic relief but do not treat underlying hyper‑secretion.
• Octreotide or lanreotide (somatostatin analogs) – suppress gastrin release and may shrink gastrinomas, especially in metastatic disease.
• Hydration and electrolyte replacement – crucial for patients with chronic diarrhea.

Surgical Options

• Localized tumor resection – enucleation or pancreaticoduodenectomy (Whipple) for tumors confined to the pancreas or duodenum.
• Debulking surgery – reduces tumor burden when complete removal is impossible.
• Liver metastasis treatment – hepatic resection, radiofrequency ablation, or hepatic artery embolization.

Targeted & Systemic Therapies

• Everolimus or sunitinib – approved for advanced pancreatic neuroendocrine tumors.
• Peptide receptor radionuclide therapy (PRRT) – delivers radioactive isotopes to somatostatin‑receptor‑positive tumors.
• Chemotherapy – reserved for rapidly progressive or poorly differentiated disease.

Home & Lifestyle Measures

• Avoid NSAIDs, aspirin, and alcohol, which exacerbate ulcer formation.
• Eat small, frequent meals; avoid large, fatty meals that increase gastric secretion.
• Stay hydrated; replace lost fluids with oral rehydration solutions if diarrhea is severe.
• Stop smoking – nicotine impairs mucosal healing.
• Maintain a symptom diary to help your provider adjust medication doses.

Prevention Tips

Because ZES is caused by a tumor, it cannot be fully prevented, but several strategies can reduce the risk of complications and support overall gastrointestinal health:

• Limit or avoid chronic use of NSAIDs and other ulcer‑causing medications.
• Test and treat Helicobacter pylori infection promptly.
• Adopt a balanced diet rich in fruits, vegetables, whole grains, and lean protein; limit spicy and acidic foods that may irritate an already sensitive stomach.
• Screen family members for MEN1 if a genetic mutation is known.
• Stay current with routine medical check‑ups; early imaging in high‑risk individuals can detect gastrinomas before they cause severe disease.

Emergency Warning Signs